NASDAQ:BIOR Biora Therapeutics (BIOR) Stock Price, News & Analysis $1.63 +0.01 (+0.62%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends About Biora Therapeutics Stock (NASDAQ:BIOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biora Therapeutics alerts:Sign Up Key Stats Today's Range$1.55▼$1.6750-Day Range$1.62▼$6.6852-Week Range$1.43▼$19.90Volume52,333 shsAverage Volume42,794 shsMarket Capitalization$7.37 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingBuy Company OverviewBiora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Read More… JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Biora Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreBIOR MarketRank™: Biora Therapeutics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiora Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiora Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Biora Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($12.66) to ($7.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.76% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Biora Therapeutics has recently increased by 43.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.76% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Biora Therapeutics has recently increased by 43.32%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment-0.29 News SentimentBiora Therapeutics has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders51.08% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biora Therapeutics' insider trading history. Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOR Stock News HeadlinesBiora Therapeutics (NASDAQ:BIOR) Price Target Raised to $23.00November 21 at 2:13 AM | americanbankingnews.comBiora Therapeutics Faces Nasdaq Delisting ChallengesNovember 15, 2024 | markets.businessinsider.comLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! November 21, 2024 | DTI (Ad)Biora Therapeutics Reports Q3 2024 Results and UpdatesNovember 15, 2024 | markets.businessinsider.comBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | finanznachrichten.deBiora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comBiora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comBiora Therapeutics (BIOR) Scheduled to Post Quarterly Earnings on ThursdayNovember 12, 2024 | americanbankingnews.comSee More Headlines BIOR Stock Analysis - Frequently Asked Questions How have BIOR shares performed this year? Biora Therapeutics' stock was trading at $13.50 on January 1st, 2024. Since then, BIOR shares have decreased by 87.9% and is now trading at $1.63. View the best growth stocks for 2024 here. How were Biora Therapeutics' earnings last quarter? Biora Therapeutics, Inc. (NASDAQ:BIOR) issued its earnings results on Wednesday, November, 10th. The company reported ($4.60) earnings per share for the quarter, beating analysts' consensus estimates of ($4.70) by $0.10. The firm earned $0.18 million during the quarter, compared to analysts' expectations of $11.10 million. When did Biora Therapeutics' stock split? Biora Therapeutics's stock reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Biora Therapeutics? Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Biora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biora Therapeutics investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Bank of America (BAC) and Ford Motor (F). Company Calendar Last Earnings11/10/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BIOR CUSIPN/A CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$23.00 Low Stock Price Target$23.00 Potential Upside/Downside+1,311.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($13.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,110,000.00 Net MarginsN/A Pretax Margin-4,005.83% Return on EquityN/A Return on Assets-332.47% Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($23.58) per share Price / Book-0.07Miscellaneous Outstanding Shares4,520,000Free Float2,213,000Market Cap$7.37 million OptionableOptionable Beta1.27 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:BIOR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.